Reduced renal microvascular reactivity to angiotensin II in diabetic rats

Microcirculation. 1994 Jul;1(2):137-45. doi: 10.3109/10739689409148269.

Abstract

Objective: Renal hyperfiltration in early diabetes is often correlated with increased renal blood flow, reflecting dilation of resistance arterioles. This loss of arteriolar tone has been associated with an impaired reactivity to angiotensin II (Ang II). This study determined if outer cortical arterioles (preglomerular and/or postglomerular) of diabetic rats exhibit a diminished reactivity to Ang II and established if renal vascular prostaglandins account for the diminished responsiveness.

Methods: The constriction of renal microvessels to Ang II (applied to the kidney bath) was quantitated in hydronephrotic kidneys of diabetic rats (7-10 days after streptozotocin treatment) and nondiabetic rats by in vivo videomicroscopy.

Results: Interlobular, afferent, and efferent arterioles of diabetic rats were found to be less reactive to Ang II than arterioles of nondiabetic rats. Indomethacin, added to the bath to inhibit renal vascular prostaglandin synthesis, enhanced the interlobular and efferent arteriolar reactivity to the peptide among diabetic rats. Yet, after indomethacin treatment, the afferent and efferent arterioles of diabetic rats were still less reactive than control arterioles to Ang II.

Conclusions: We conclude that the blunted reactivity of afferent and efferent arterioles to Ang II among diabetic hydronephotic kidneys cannot be fully explained by the influence of renal vascular-derived dilator prostaglandins.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Angiotensin II / pharmacology*
  • Animals
  • Arterioles / drug effects
  • Capillary Resistance / drug effects
  • Diabetes Mellitus, Experimental / physiopathology*
  • Indomethacin / pharmacology
  • Kidney / blood supply*
  • Microcirculation / drug effects
  • Microscopy, Video
  • Rats
  • Vasoconstriction / drug effects
  • Vasoconstrictor Agents / pharmacology*

Substances

  • Vasoconstrictor Agents
  • Angiotensin II
  • Indomethacin